secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001867096-23-000125
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma exchanges $32M of 5% convertible notes for $33.6M of new 8% notes due 2028
--------------------------------------------------------------------------------

- Exchanged $31,975,000 of 5% Convertible Senior Notes due 2025 for $33,574,000 of new 8.00% Convertible Senior Notes due 2028.
- New notes bear 8.00% interest, payable semi-annually; maturity July 15, 2028.
- Initial conversion rate is 326.7974 shares per $1,000 principal, implying ~$3.06 per share.
- Notes are senior unsecured, guaranteed by Xeris Pharmaceuticals, issued to QIBs via Section 4(a)(2) exemption.
- Company may redeem notes after July 20, 2026 if stock price exceeds 130% of conversion price for 20 of 30 trading days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000125/0001867096-23-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000125/xers-20230929.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer